Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTGIR | P43119 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8437918 | 0.82 | OPRM1 (0.51) | HRH3OPRM1SIGMAR1ALDH1A1POLB | |
| SCHEMBL30965977 | 0.77 | ADRA2A (0.57) | OPRM1SIGMAR1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6566757 | 0.76 | ADRA2A (0.59) | OPRM1SIGMAR1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL11195264 | 0.73 | ALDH1A1 (0.83) | ALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL10694181 | 0.72 | OPRM1 (0.54) | OPRM1SIGMAR1ALDH1A1PTGIR | |
| SCHEMBL18390308 | 0.72 | TACR1 (0.56) | ALDH1A1 | |
| SCHEMBL20236474 | 0.72 | LTB4R2 (0.50) | ALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL5758121 | 0.72 | ADRA2C (0.61) | ALDH1A1POLBPTGIRKMT2AADRA2A | |
| SCHEMBL11661567 | 0.72 | ALDH1A1 (0.87) | ALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL10798764 | 0.72 | OPRM1 (0.45) | HRH3OPRM1SIGMAR1ALDH1A1PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | HRH3 2081/4885OPRM1 1495/4885SIGMAR1 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.